A female farmer in a large greenhouse bent down checking tomato plants

For patients with asthma who prefer an MDI

Seretide Evohaler is over £5 cheaper than Fostair at medium dose1,2

What can Seretide Evohaler offer patients who prefer an MDI?


Seretide Evohaler Indication in Asthma3

For the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:

Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist
Patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist


Seretide Evohaler comes in three different doses, allowing flexibility of dosing for your patient with asthma at low, medium and high dose inhaled steroid.3

The recommended dose of Seretide Evohaler 25/50mcg, 25/125mcg and 25/250mcg is two inhalations, twice daily for patients 12 years and above.3

Seretide Evohaler 25/50mcg two inhalations, twice daily, is also licensed for use in paediatric asthma for patients 4 years and above.3

Image of three Seretide (salmeterol/fluticasone propionate)  Evohalers. Seretide doses shown are 25/50mcg, 25/125mcg & 25/250mcg

Seretide Evohaler - price no longer a barrier to prescribe

30 day supply for adult asthma at medium dose1,2

Image depicting a price comparison of Seretide (salmeterol/fluticasone propionate) Evohaler 25/125mcg (2 puffs b.d) at £23.45. versus Fostair 100/6mcg (2 puffs b.d) at £29.32 for a 30 day supply for adult asthma at medium dose. Additional image of Seretide Evohaler 25/125mcg.

Discover more about Seretide


  1. MIMS; Fostair 100/6 list price per pack for the treatment of asthma (accessed March 2022)
  2. BTS/SIGN Guidelines for the Management of Asthma 2019. Table 12 (comparison of medium doses)
  3. Seretide Evohaler SPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

Trademarks are owned by or licensed to the GSK group of companies.

March 2022 | PM-GB-FPS-WCNT-210001 (V1.0)